Group 1 - The company repurchased 535,000 shares at approximately HKD 5 per share, totaling over HKD 2.68 million, with a cumulative repurchase of nearly 2 million shares in December, exceeding HKD 10 million [1] - The company's total revenue for the fiscal year 2026 reached RMB 358 million, representing a year-on-year growth of 8.7%, with adjusted EBITDA of approximately RMB 54 million, doubling from the previous year [1] - The release of the first version of the commercial insurance innovative drug catalog in China is expected to provide new growth opportunities for the company, enhancing its ability to assist insurance companies in risk pricing and medical cost control [1] Group 2 - The company has provided comprehensive solutions for the "Hui Min Bao" projects in various provinces, serving over 40 million insured users [2] - The "Shenzhen Hui Min Bao," operated by the company, has included all 19 innovative drugs from the first version of the commercial insurance innovative drug catalog in its coverage for the 2025 fiscal year [2] - The company offers full-chain support for pharmaceutical companies, including clinical research services and market access strategies, enhancing the efficiency of drug development and commercialization [2]
医渡科技(02158)12月以来6次回购 累计斥资超1000万港元